Delivery Order SPE2DB20D1100-SPE2DB25FC2S4
- Not listed
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a $11,827.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform work at its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $3,523.82 to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency awarded a $6,049.03 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens (2 mL units) with a firm fixed price structure and an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with the federal government. The order will be fulfilled from the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of DUPIXENT 300 mg/2 mL pen injections with a ceiling value of $2,007.95. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. As a child contract, this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,931.71 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pen auto-injectors (2 mL) on September 2, 2025, with completion targeted for September 3, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $22,738.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML). The contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025, and is being fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing Indefinite Delivery Contract...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FC2S4Delivery Order
The Defense Logistics Agency awarded a $7,883.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of DUPIXENT 300 mg/2 mL pens (2 mL units). This contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The point of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of May 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's prime IDC vehicle enables it to supply a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare programs globally. This delivery order for DUPIXENT, a biologic immunosuppressant medication used in treating conditions such as atopic dermatitis and eosinophilic asthma, reflects the company's ongoing fulfillment of specialized pharmaceutical needs for defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 5/12/25 |